Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer-FRQS Innovation Fund has selected two research projects to develop a new therapeutic strategy for HIV and a molecular test to determine the outcomes of skin cancer.
Subscribe to our email newsletter
The innovation fund, created in March 2008, intends to support human health research projects in Québec.
The first research project is named Impact des inhibiteurs intracellulaires du DCIR dans la pathogenèse de l’infection au VIH-1 [Effects of intracellular inhibitors of DCIR in the pathogenesis of HIV-1 infection].
The other project is entitled Développement d’un nouveau test moléculaire basé sur la technologie d’analyse de l’ADN par annelage, sélection, extension et épissage (DASL) pour la prédiction de l’issue de la maladie chez les patients porteurs de lymphomes cutanés à cellules T [Development of a new molecular test based on DNA annealing, selection and ligation technology to predict illness outcomes in patients with cutaneous T-cell lymphoma].
Fonds de recherche du Québec – Santé chief scientist and chairman of the board of directors Rémi Quirion said seven projects have been funded as part of three Pfizer-FRQS Innovation Fund competitions.